Video-assisted speech therapy for patients with ORL cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study evaluates the effectiveness of video-assisted remote speech therapy consultations for patients with ORL cancer, specifically focusing on issues related to phonation and swallowing. Patients will receive consultations from both a private speech therapist and an expert therapist, with their satisfaction assessed through a questionnaire. The study aims to determine how this remote approach can address the complex needs of patients undergoing treatment for advanced ORL cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years at study entry.
2. Patient with carcinological pathology of the VADS, relevant to surgery and/or radiotherapy and/or chemotherapy.
3. Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).
4. Patient affiliated to a Social Security system in France.
5. Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure.

Exclusion Criteria:

1. Pregnant or lactating women.
2. Any psychological, familial, geographical or sociological condition that does not allow for compliance with the medical follow-up and/or procedures foreseen in the study protocol.
3. Patients deprived of their liberty or under legal protection (guardianship and tutorship, safeguard of justice).

Where it's running

• Institut Universitaire du Cancer de Toulouse - Oncopole
  Toulouse, France Recruiting

Study contacts

• Study coordinator: Jérôme SARINI
• Email: sarini.jerome@iuct-oncopole.fr
• Phone: 05 31 15 60 16

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Onco-sexology program for laryngectomy patients and their partners

  This study is trying out a special program to see if it can help laryngectomy patients and their partners feel better about their intimate lives after surgery.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06517355

• Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

  Researchers test whether analyzing DNA from cervical smears with shallow whole-genome sequencing can help detect high-grade serous ovarian cancer early in patients undergoing treatment for this cancer.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07821879

• Male Breast Cancer Predisposition Factor: Create a Control Group

  This study tests genetic and psychosocial data in men who are relatives of men with breast cancer but who themselves have no cancer history.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07558343

• Biomarkers and immune responses in early-stage solid cancers treated with immunotherapy

  This study tests immune biomarkers in patients with early-stage solid cancers who are receiving immune checkpoint blockade before surgery.

  Recruiting Institut Claudius Regaud · Toulouse and 2 other locations · NCT07427186

• Atlas of cell organelles and protein patterns in breast cancer subtypes

  This project will collect tumor and blood samples from people with early or newly metastatic breast cancer to test how much fat accumulates in tiny cell structures (lipid droplets) and to map protein patterns across tumor subtypes.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07233928

• Comparing blood levels of the free‑DXd payload from trastuzumab‑deruxtecan by BMI in people with advanced or metastatic breast cancer

  This study will test whether body mass index changes blood levels of the free‑DXd payload in adults with locally advanced or metastatic HER2‑low or HER2‑positive breast cancer who are receiving trastuzumab‑deruxtecan.

  Recruiting at 6 sites Phase 4 Institut Claudius Regaud · Angers and 9 other locations · NCT07195344

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.